BCTX: November 2023 SITC Poster
NASDAQ:BCTX
SITC Poster Presentation
BriaCell Therapeutics Corp. (NASDAQ:BCTX) presented a poster at the 2023 Society for Immunotherapy of Cancer (SITC) annual meeting held in San Diego, California. It was entitled Development and Mechanism of Action of a Novel Cellular Immunotherapeutic Platform for the Treatment of Advanced Solid Tumors and addressed immune system activation in tumor models by BriaCell’s next generation breast and prostate cancer immunotherapies. BriaCell’s two featured vaccine candidates include Bria-IMT, which offers enhanced efficacy in human leucocyte (HLA) matched patients and Bria-OTS, an off the shelf personalized immunotherapy providing HLA-matched targeting to over 99% of the US population. The vaccine functions using two synergistic mechanisms - it facilitates the cross-presentation of cancer cell antigens by host immune cells and directly activates the immune system.
In the latest poster presentation, the authors identified the process they used to engineer Bria-OTS and demonstrated the ability of the product to activate a range of immune cells including natural killer T cells and T cells.
BriaCell developed several conclusions in its poster including the multimodal mechanisms of action associated with Bria-OTS that can stimulate robust immune responses. Due to its broad matching with HLA antigens, Bria-OTS is expected to be able to match with over 99% of the US population. Safety is another favorable attribute for the candidate and patients generally only suffer injection site reactions and other low grade side effects in contrast to more difficult profiles of chemotherapies and hormone-based treatments. Finally, Bria-OTS is expected to be a rapidly available, cost-effective treatment that can be taken off the shelf for immediate administration.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
________________________
1. BriaCell Poster presented at SITC 2023. Development and Mechanism of Action of a Novel Cellular Immunotherapeutic Platform for the Treatment of Advanced Solid Tumors.
